Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 994M 888M 816M 741M 1.39B 94.16B 1.43B 9.74B 3.92B 49.7B 3.73B 3.65B 158B P/E 2026 *
-6.31x
P/E 2027 * -5.63x
Enterprise Value 994M 888M 816M 741M 1.39B 94.16B 1.43B 9.74B 3.92B 49.7B 3.73B 3.65B 158B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.41%
Yield 2026 *
-
Yield 2027 * -
10-27 Wedbush Adjusts Price Target on ORIC Pharmaceuticals to $14 From $17, Keeps Outperform Rating MT
10-23 ORIC Pharmaceuticals, Inc. - Special Call
10-23 Oric Pharmaceuticals, Inc. Presents Potential Best-In-Class Data for Enozertinib in First-Line Nsclc Patients with Egfr Atypical Mutations At Esmo Congress 2026 and Plans to Advance Enozertinib into Global Phase 3 Trial CI
10-23 Oric Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer At Esmo Congress 2026 CI
10-23 ORIC to Advance Lung Cancer Drug Candidate to Phase 3 Trial MT
10-05 Oric Pharmaceuticals, Inc. and Cancer Research Uk Announce Agreement to Advance A Potential First-In-Class Cip2a-Targeted Therapy into Clinical Development CI
10-05 Leerink Partners Initiates ORIC Pharmaceuticals at Outperform With $26 Price Target MT
09-23 BTIG Initiates ORIC Pharmaceuticals at Buy With $26 Price Target MT
09-15 ORIC Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:00 AM
08-28 Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing MT
08-03 ORIC Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-14 ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer MT
07-14 Oric Pharmaceuticals Initiates Himalayas-1 Global Phase 3 Trial in Patients with Mcrpc Previously Treated with Abiraterone CI

Last Transcript: ORIC Pharmaceuticals, Inc.

1 day+5.73%
1 week+6.56%
Current month+3.79%
1 month-21.43%
3 months-9.53%
6 months-1.84%
Current year+17.24%
1 week 8.28
Extreme 8.275
10
1 month 8.28
Extreme 8.275
14.31
Current year 7.23
Extreme 7.23
14.68
1 year 7.23
Extreme 7.23
14.68
3 years 3.9
Extreme 3.8951
16.65
5 years 2.36
Extreme 2.36
18.58
10 years 2.36
Extreme 2.36
40.81
Manager TitleAgeSince
Chief Executive Officer 47 2018-05-06
Director of Finance/CFO 52 2019-08-31
Chief Tech/Sci/R&D Officer - 2025-08-17
Director TitleAgeSince
Chairman 68 2018-03-06
Director/Board Member 47 2018-05-06
Director/Board Member 62 2020-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/1/26 Exercice

Founder

13,700 0.0132%
9/28/26 Exercice

Chief Financial Officer

40,200 0.0388%
9/24/26 Exercice

Chief Financial Officer

1,800 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
+5.73%+6.56%-24.43%+35.45% 994M
-2.43%-4.38%+40.32%+55.64% 60.57B
+1.98%+5.34%+22.85%+100.18% 55.51B
+4.39%+3.36%+12.18%+78.30% 55.22B
+1.61%-3.30%+22.77%+33.16% 43.27B
-1.74%-3.02%+13.83%+93.17% 40.36B
+3.22%+4.30%+227.37%+776.49% 41.63B
-0.59%-4.42%+95.76%+84.67% 33.29B
-1.09%+0.69%+14.20%+45.26% 32.27B
-4.46%+9.98%-43.92%+320.28% 22.91B
Average +0.87%+3.70%+38.09%+162.26% 38.6B
Weighted average by Cap. +0.72%+2.17%+46.65%+161.72%

Financials

2026 *2027 *
Net sales - -
Net income -166M -148M -136M -124M -233M -15.74B -238M -1.63B -655M -8.31B -624M -610M -26.33B -201M -180M -165M -150M -282M -19.08B -289M -1.97B -794M -10.07B -756M -740M -31.91B
Net Debt - -
Projected Income Statement - Annual - ORIC Pharmaceuticals, Inc.
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
111
Date Price Change Volume
26-11-03 US$9.590 +5.73% 3,555,588
26-11-02 US$9.070 -1.84% 1,922,758
26-10-30 US$9.240 +2.78% 2,441,596
26-10-29 US$8.990 -3.33% 1,046,758
26-10-28 US$9.300 +3.33% 1,413,970
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - ORIC Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
9.590USD
Average target price
21.71USD
Spread / Average Target
+126.43%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ORIC Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ORIC Stock